Teladoc Health (NYSE:TDOC) Raised to “Buy” at Bank of America

Teladoc Health (NYSE:TDOC) was upgraded by analysts at Bank of America from a “neutral” rating to a “buy” rating in a note issued to investors on Thursday, MarketBeat reports. The brokerage presently has a $7.00 price objective on the health services provider’s stock. Bank of America‘s price objective suggests a potential upside of 32.95% from the stock’s current price.

Several other equities research analysts have also weighed in on TDOC. Barclays assumed coverage on Teladoc Health in a report on Tuesday, December 9th. They issued an “equal weight” rating and a $8.50 target price for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Teladoc Health in a report on Monday, December 29th. BMO Capital Markets assumed coverage on shares of Teladoc Health in a report on Thursday, November 13th. They issued a “market perform” rating and a $8.00 target price on the stock. Evercore decreased their price target on shares of Teladoc Health from $9.00 to $8.00 and set an “in-line” rating for the company in a report on Thursday, October 30th. Finally, Citigroup lowered their price target on Teladoc Health from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Friday, January 9th. Four investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $8.50.

Teladoc Health Stock Up 13.2%

Shares of NYSE TDOC traded up $0.62 during trading hours on Thursday, hitting $5.27. The stock had a trading volume of 13,602,156 shares, compared to its average volume of 6,744,879. The firm’s 50-day moving average price is $6.06 and its two-hundred day moving average price is $7.22. Teladoc Health has a 52 week low of $4.40 and a 52 week high of $10.02. The company has a market capitalization of $934.38 million, a P/E ratio of -4.11 and a beta of 2.12. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.60 and a current ratio of 2.70.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, February 25th. The health services provider reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.05. The company had revenue of $642.27 million for the quarter, compared to analyst estimates of $635.33 million. Teladoc Health had a negative net margin of 8.84% and a negative return on equity of 10.59%. Teladoc Health’s quarterly revenue was up .3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.28) EPS. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Analysts anticipate that Teladoc Health will post -1.16 EPS for the current fiscal year.

Insider Buying and Selling at Teladoc Health

In other news, insider Fernando M. Rodrigues sold 4,209 shares of Teladoc Health stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $7.48, for a total transaction of $31,483.32. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Charles Divita III sold 17,138 shares of the stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $7.63, for a total transaction of $130,762.94. Following the completion of the transaction, the chief executive officer directly owned 201,036 shares of the company’s stock, valued at $1,533,904.68. This trade represents a 7.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 33,288 shares of company stock valued at $251,684 over the last quarter. 0.58% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Teladoc Health

Several large investors have recently made changes to their positions in TDOC. Teacher Retirement System of Texas increased its position in shares of Teladoc Health by 5.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 26,592 shares of the health services provider’s stock worth $232,000 after purchasing an additional 1,431 shares in the last quarter. Federated Hermes Inc. boosted its stake in Teladoc Health by 0.5% in the third quarter. Federated Hermes Inc. now owns 307,700 shares of the health services provider’s stock worth $2,379,000 after purchasing an additional 1,450 shares in the last quarter. Creative Planning grew its holdings in shares of Teladoc Health by 7.7% during the third quarter. Creative Planning now owns 20,567 shares of the health services provider’s stock worth $159,000 after purchasing an additional 1,462 shares during the last quarter. Krane Funds Advisors LLC increased its stake in shares of Teladoc Health by 13.4% in the third quarter. Krane Funds Advisors LLC now owns 12,431 shares of the health services provider’s stock valued at $106,000 after buying an additional 1,469 shares in the last quarter. Finally, State of Wyoming raised its holdings in shares of Teladoc Health by 2.1% in the third quarter. State of Wyoming now owns 79,075 shares of the health services provider’s stock valued at $611,000 after buying an additional 1,628 shares during the last quarter. Institutional investors own 76.82% of the company’s stock.

Teladoc Health News Summary

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 results beat expectations — Teladoc reported revenue of $642.3M (above $635.3M consensus) and EPS of ($0.14), topping estimates. The beat reduces near‑term earnings uncertainty and provides proof of stabilization after prior losses. Q4 sales surprise
• Positive Sentiment: Conference call highlighted growth in Integrated Care and strategic repositioning of BetterHelp — management emphasized areas of improving unit economics and product focus that could drive margin recovery over time. Investors often reward visible operational progress even when near‑term guidance is cautious. Earnings call highlights
• Neutral Sentiment: Deeper metric readouts available — analysts and outlets (e.g., Zacks) are parsing subscriber, utilization and margin metrics to assess sustainability of the beat; these details will influence revisions to models but don’t yet change the headline picture. Zacks analysis
• Negative Sentiment: Forward guidance disappointed — Q1 2026 EPS guidance of -0.450 to -0.350 and FY 2026 EPS of -1.100 to -0.700 both sit below consensus; Q1 revenue guidance ($598M–$620M) is also below Street estimates. This increases near‑term downside risk and keeps profitability recovery uncertain. Guidance details
• Negative Sentiment: Analysts cut price targets — Wells Fargo and Stifel reduced targets from $8 to $6 and kept neutral/hold stances, signaling tempered expectations for upside and contributing to mixed sell‑side sentiment. Benzinga

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.